Cowen resumed coverage on SOPHiA GENETICS SA
$SOPH
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cowen resumed coverage of SOPHiA GENETICS SA with a rating of Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/18/2024 | $11.00 | Buy | Craig Hallum |
| 8/7/2024 | $10.00 → $5.00 | Overweight → Equal-Weight | Morgan Stanley |
| 6/27/2024 | $6.00 | Buy | Guggenheim |
| 11/29/2023 | $8.00 | Outperform | RBC Capital Mkts |
| 7/5/2023 | $10.00 | Overweight | JP Morgan |
| 1/3/2023 | $6.00 | Buy | BTIG Research |
| 11/23/2022 | $2.00 | Neutral | Credit Suisse |
| 2/15/2022 | $23.00 → $18.00 | Overweight | Morgan Stanley |
SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center Aim to Establish Precision Medicine Hub for the Next Generation of Precision OncologyNEW YORK, June 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint venture between the two institutions. The joint venture aims to build upon the strength of MSK innovation in clinical diagnostics and SOPHiA GENETICS's Ai platform to potentially discover, develop, and deploy a new generation of precision oncology to patients around the world.
LONDON, May 13, 2026 /CNW/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today announced a partnership with Synnovis, one of England's leading pathology providers, to bring liquid biopsy testing to lung and breast cancer patients across the U.K. as part of NHS England's 'revolutionary blood test-first' program. Synnovis, a major provider for England's South East Genomic Medicine Service, worked with SOPHiA GENETICS to launch the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™. This innovative test, originally developed by Memorial Slo
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year periodIFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year"We st
Craig Hallum initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $11.00
Morgan Stanley downgraded SOPHiA GENETICS SA from Overweight to Equal-Weight and set a new price target of $5.00 from $10.00 previously
Guggenheim initiated coverage of SOPHiA GENETICS SA with a rating of Buy and set a new price target of $6.00
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
6-K - SOPHiA GENETICS SA (0001840706) (Filer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
4 - SOPHiA GENETICS SA (0001840706) (Issuer)
BOSTON and ROLLE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company and leader in data-driven medicine, today announced that Ross Muken, previously Chief Financial Officer ("CFO") and Chief Operating Officer ("COO"), has been promoted to company President, effective November 5, 2024. George Cardoza has been appointed as the company's new CFO. In the newly created role of company President, Ross Muken will oversee SOPHiA GENETICS's global business operations and work even more closely on strategic planning with CEO, Jurgi C
New collective intelligence network to enable the most advanced research in oncology in support of precision medicine BOSTON and ROLLE, Switzerland, May 30, 2024 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced SOPHiA UNITY, a new data-driven consortium designed to accelerate cancer research globally. SOPHiA UNITY aims to bring together leading healthcare institutions to progress a shared goal of furthering cancer research, advancing drug development and supporting data-driven patient care.
Microsoft's Deputy Chief Technology Officer to be appointed at Annual Shareholders' Meeting BOSTON and LAUSANNE, Switzerland, May 31, 2023 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the nomination of Lila Tretikov to its Board of Directors. The Board of Directors has proposed the appointment of Tretikov as a member of the board at the Annual General Meeting of Shareholders of SOPHiA GENETICS SA on June 26, 2023. An award-winning powerhouse in the global technology
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
SC 13G/A - SOPHiA GENETICS SA (0001840706) (Subject)
BOSTON and ROLLE, Switzerland, May 5, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 68.0% on a reported basis and 75.4% on an adjusted basis, compared to 68.7% reported and 75.7% adjusted in the prior year periodIFRS net loss was $19.3 million, an increase of 11% year-over-year; Adjusted EBITDA loss was $9.2 million, improving 3% year-over-year"We st
BOSTON and ROLLE, Switzerland, April 21, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the first quarter 2026 before U.S. markets open on Tuesday, May 5, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcast live on the SOPHiA GENETICS Investor Relations Website. Additionally, a replay will be available on the websi
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial ResultsRevenue was $21.7 million, up 22% year-over-yearGross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2% reported and 74.2% adjusted in the prior year periodIFRS net loss was $19.2 million, an increase of 27% year-over-year; Adjusted EBITDA loss was $9.9 million, an increas